Are transfusions common in dialysis patients, and what is the typical approach?

• A. Transfusions are routinely given to all dialysis patients
• B. Transfusions are avoided if possible; manage anemia with ESA and iron; transfusion is reserved for symptomatic anemia or acute blood loss
• C. ESA is avoided
• D. Iron is not used

Answer: (B)

In dialysis patients, anemia is treated by stimulating red blood cell production and ensuring there is enough iron to support that process, rather than routinely giving blood transfusions. Erythropoiesis-stimulating agents (ESAs) are used to raise hemoglobin levels, and iron is provided (often intravenously during dialysis) to correct iron deficiency and optimize response to ESAs. Transfusions are avoided if possible because donor blood carries risks such as reactions and alloimmunization, which can complicate future transplant eligibility and make ESA therapy less effective. Transfusions are reserved for situations with symptomatic anemia or acute blood loss when the immediate need outweighs long-term risks. The other options are inconsistent with standard practice: transfusing all patients routinely ignores risks; avoiding ESA misses the main treatment to stimulate production; and omitting iron neglects a key support for erythropoiesis.